Cover Image
Market Research Report

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 520770
Published Content info 74 Pages
Delivery time: 1-2 business days
Price
Back to Top
Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020
Published: March 31, 2020 Content info: 74 Pages
Description

Summary:

According to the recently published report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 7 molecules.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Respiratory which include indications Alzheimer's Disease, Depression, Overactive Bladder, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Axillary Hyperhidrosis, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Obstructive Sleep Apnea, Pain, Psychosis, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Urinary Incontinence.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2321TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • Apnimed Inc
  • Dermavant Sciences Inc
  • FemmePharma Global Healthcare Inc
  • Karuna Therapeutics Inc
  • TheraVida Inc
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
  • (atomoxetine + oxybutynin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (oxybutynin + pilocarpine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (pilocarpine + tolterodine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANAVEX-141 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • blarcamesine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Anavex Life Sciences Corp, H1 2020
  • Pipeline by Apnimed Inc, H1 2020
  • Pipeline by Dermavant Sciences Inc, H1 2020
  • Pipeline by FemmePharma Global Healthcare Inc, H1 2020
  • Pipeline by Karuna Therapeutics Inc, H1 2020
  • Pipeline by TheraVida Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
Back to Top